State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer

*Elena Castro,1,2 Nuria Romero,1,2 David Olmos1,2

1. Prostate Cancer and Genitourinary Tumours Unit, Clinical Research Programme, Spanish National Cancer Research Centre, Madrid, Spain
2. Prostate cancer unit, Clara Campal Comprehensive Cancer Center, HM Universitario Sanchinarro, Madrid, Spain
*Correspondence to ecastro@cnio.es

Disclosure: No potential conflict of interest.
Received: 22.05.14 Accepted: 09.09.14
Citation: EMJ Oncol. 2014;2:100-105.

Abstract

Prostate cancer (PrCa) is the most common cancer type in men in developed countries. In the last few years, a dramatic change has occurred in the understanding of castration-resistant PrCa which has led to the development of new drugs that have an impact on patient survival. This review summarises the recent advances in the management of the disease.

Download (PDF, 88KB)

Comments are closed.